Posco Holdings Up Over 9%, on Track for Highest Close Since August 2011 — Data Talk
POSCO Holdings Inc. Sponsored ADR (PKX) is currently at $106.05, up $9.18 or 9.48%
--Would be highest close since Aug. 3, 2011, when it closed at $107.97
--On pace for largest percent increase since April 13, 2020, when it rose 10.72%
--Currently up seven of the past eight days
--Up 43.41% month-to-date
--Up 94.69% year-to-date
--Down 45.86% from its all-time closing high of $195.89 on Oct. 2, 2007
--Up 138.53% from 52 weeks ago (July 22, 2022), when it closed at $44.46
--Would be a new 52-week closing high
--Up 189.67% from its 52-week closing low of $36.61 on Sept. 30, 2022
--Traded as high as $106.85; highest intraday level since Aug. 3, 2011, when it hit $108.84
--Up 10.3% at today's intraday high; largest intraday percent increase since April 10, 2023, when it rose as much as 10.92%
All data as of 12:44:09 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
July 21, 2023 13:02 ET (17:02 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track